Skip to main content
. Author manuscript; available in PMC: 2011 Mar 2.
Published in final edited form as: J Natl Compr Canc Netw. 2009 Oct;7(Suppl 7):S1–S30. doi: 10.6004/jnccn.2009.0080

Figure 4.

Figure 4

Estimated percent change and 95% confidence intervals from baseline to 12 months in lumbar spine and total hip bone mineral density (BMD).

aP-values from paired t-rest for open-label, non-comparative groups.

bP-values from ANCOVA in favor of anastrozole plus risedronate.

Reproduced with permission from Van Poznak C, Hannon RA, Clack G, et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis [abstract]. Presented at 30th Annual San Antonio Breast Cancer Symposium;

December 13–16, 2007; San Antonio, Texas. Abstract 502.